Ex Parte 7,736,389 B1 et alDownload PDFPatent Trial and Appeal BoardSep 26, 201495002082 (P.T.A.B. Sep. 26, 2014) Copy Citation UNITED STATES PATENT AND TRADEMARK OFFICE UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 95/002,082 08/22/2012 7,736,389 B1 PRES06-00513 1040 7590 09/26/2014 Edwin H. Crabtree 3773 Cherry Creek N. Drive Suite 575 Denver, CO 80209 EXAMINER FLANAGAN, BEVERLY MEINDL ART UNIT PAPER NUMBER 3993 MAIL DATE DELIVERY MODE 09/26/2014 PAPER Please find below and/or attached an Office communication concerning this application or proceeding. The time period for reply, if any, is set in the attached communication. PTOL-90A (Rev. 04/07) UNITED STATES PATENT AND TRADEMARK OFFICE ____________________ BEFORE THE PATENT TRIAL AND APPEAL BOARD ____________________ REFOCUS OCULAR, INC. Requester, Respondent v. READING ENHANCEMENT CO. Patent Owner, Appellant ____________________ Appeal 2014-006759 Reexamination Control 95/002,082 US Patent No. 7,736,389 B1 1 Technology Center 3900 ____________________ Before: STEVEN D. A. MCCARTHY, DANIEL S. SONG, and BRETT C. MARTIN, Administrative Patent Judges. MARTIN, Administrative Patent Judge. DECISION ON APPEAL 1 Issued on June 15, 2010 to Richard E. Damiano (hereinafter referred to as the '389 patent). Appeal 2014-006759 Reexamination Control 95/002,082 US Patent No. 7,736,389 B1 2 STATEMENT OF THE CASE Patent Owner appeals under 35 U.S.C. §§ 134(b) and 315(a) from the Examiner’s rejection of claim 1. We have jurisdiction under 35 U.S.C. §§ 134(c) and 315(b). US Patent No. 8,167,938, which is a continuation of the '389 patent, is also on appeal as Appeal Number 2014- 006856. We REVERSE. THE INVENTION Appellant’s invention is directed to "a reading enhancement device sutured to the sclera of the eye for preventing and/or treating presbyopia and more particularly… for buckling and compressing a portion of the sclera and the ciliary body inwardly and perpendicular to the plane of the sclera." Spec. col. 1, ll. 16-22. Claim 1 is the only claim in the '389 patent and is reproduced below: 1. A suture device for preventing and/or treating presbyopia of the eye, the suture device configured for suturing to the outer wall of the sclera to effect buckling and compressing a portion of the sclera and the suture device having a convex portion shaped to force the ciliary body inwardly thereby exerting a posterior compression force perpendicular to the sclera, wherein the compression force strengthens the muscle of the ciliary body by reducing the stretching of the scleral spur occurring with age, the suture device comprising: an I-beam shaped compression body having an elongated semi-circular convex center portion, the center portion of the I-beam terminating in transverse first and second ends wherein the first end is adapted for receiving a first suture thereon and the second end is adapted for receiving a second suture thereon; wherein each of the first end and second end having a configuration preventing Appeal 2014-006759 Reexamination Control 95/002,082 US Patent No. 7,736,389 B1 3 the first suture and the second suture from slipping off the center portion, respectively; the semi-circular convex center portion having a tissue engaging surface extending outwardly from a front of the center portion and extending between the transverse first and second ends; and whereby when the transverse first end is sutured to the outer wall of the sclera using the first suture and the transverse second end is sutured to the outer wall of the sclera using the second suture, the tissue engaging surface of the semi-circular convex portion is compressed against a portion of the outer wall of the sclera thereby exerting a compression force to the sclera. REFERENCES The prior art relied upon by the Examiner in rejecting the claims on appeal is: Schachar US 7,416,560 B1 Aug. 26, 2008 Zdenek Caro Straub US 2002/0002403 A1 US 2006/0004386 A1 WO 01/17460 A1 Jan. 3, 2002 Jan. 5, 2006 Mar. 15, 2001 THE REJECTIONS ON APPEAL The Examiner made the following rejections: 1. Claim 1 stands rejected under 35 U.S.C. § 103(a) as being unpatentable over Zdenek and Straub. RAN 5. 2. Claim 1 stands rejected under 35 U.S.C. § 103(a) as being unpatentable over Zdenek, Straub, and Caro. RAN 7. 3. Claim 1 stands rejected under 35 U.S.C. § 103(a) as being unpatentable over Schachar and Straub. RAN 10. 4. Claim 1 stands rejected under 35 U.S.C. § 103(a) as being unpatentable over Schachar, Straub, and Caro. RAN 12. Appeal 2014-006759 Reexamination Control 95/002,082 US Patent No. 7,736,389 B1 4 ANALYSIS Claim Construction Before turning to the rejections, it is necessary in this case to deal with claim construction, namely whether the preamble of claim 1 is to be given any weight. It is undisputed that the references at issue collectively (via specific teachings in Straub) teach a device that has a convex surface that is capable of some form of compression. What is at issue, however, is not whether compression occurs, but the type of compression such a device would impart to the eye. Claim 1, in its preamble, details the type of compression (e.g., "for preventing and/or treating presbyopia," "to effect buckling and compressing a portion of the sclera," and "to force the ciliary body inwardly thereby exerting a posterior compression force perpendicular to the sclera"), but the body of the claim does not include the same level of detail and requires only "exerting a compression force to the sclera." According to the Examiner, "[t]he only function that is properly recited in claim 1 is 'exerting a compressive force to the sclera.'" RAN 17. The Examiner also states, "the preamble of claim 1…is given no patentable weight." Id. Both the Requester and the Examiner agree that regarding this limited form of compression, "Zdenek and Straub inherently perform this function." Id. The Patent Owner disagrees and asserts that "the configuration recited in the preamble and body of the claims is significant, and the preamble must be read as a limitation affecting patentability." App. Br. 18. If the claim preamble, when read in the context of the entire claim, recites limitations of the claim, or, if the claim preamble is “necessary to Appeal 2014-006759 Reexamination Control 95/002,082 US Patent No. 7,736,389 B1 5 give life, meaning, and vitality” to the claim, then the claim preamble should be construed as if in the balance of the claim. Pitney Bowes, Inc. v. Hewlett- Packard Co., 182 F.3d 1298, 1305 (Fed. Cir. 1999) (citation omitted). In this particular case, the preamble details a specific type of compression that is created on the sclera via the device's convex surface. While the claim body recites only "exerting a compressive force to the sclera," we conclude that this recitation relates back to the preamble's description of compression because the preamble "gives life, meaning, and vitality" to the claim. Accordingly, the broadest reasonable interpretation in view of the specification of the '389 patent requires consideration of the preamble language to be limiting and the force applied must be as described in the preamble and of the type that would be used to treat presbyopia. Rejections Rejections 1 and 2 rely on the teaching in Zdenek that describes a suture device whereby, in an alternative embodiment, "the bottom surface of the central body portion may be convex along the long axis of the prosthesis." Para. 40. It is important to note, as Patent Owner points out, that Zdenek, as well as Straub and Schachar, discloses a device for treating presbyopia in the exact opposite way as that of the '389 patent. Namely, Zdenek's device is used to expand the sclera, not compress it, which is apparent from the title, "Scleral Expansion Device Having Duck Bill." Although Zdenek discloses a convex surface, a reasonable conclusion would be that even with a convex bottom surface, the device still results in expansion, not compression. From this scant disclosure, as well as Zdenek's disclosed outcome of expansion, we simply cannot agree that Zdenek Appeal 2014-006759 Reexamination Control 95/002,082 US Patent No. 7,736,389 B1 6 teaches a device capable of exerting the compression recited in the preamble for treating presbyopia. As the Patent Owner further notes, "[t]he examiner's argument [regarding Zdenek's compression] is pure speculation." App. Br. 14. The fact that a certain result or characteristic may occur or be present in the prior art is not sufficient to establish the inherency of that result or characteristic. In re Rijckaert, 9 F.3d 1531, 1534 (Fed. Cir. 1993) (rejection reversed because alleged inherency was based on what would result due to optimization of conditions, not what was necessarily present in the prior art); see also, In re Oelrich, 666 F.2d 578, 581-82 (CCPA 1981). To establish inherency, the extrinsic evidence must make clear that the missing descriptive matter is necessarily present in the thing described in the reference, and that it would be so recognized by persons of ordinary skill. Inherency, however, may not be established by probabilities or possibilities. The mere fact that a certain thing may result from a given set of circumstances is not sufficient. In re Robertson, 169 F.3d 743, 745 (Fed. Cir. 1999) (citations and internal quotations omitted). In relying upon the theory of inherency, the Examiner must provide a basis in fact and/or technical reasoning to reasonably support the determination that the allegedly inherent characteristic necessarily flows from the teachings of the applied prior art. Ex parte Levy, 17 USPQ2d 1461, 1464 (Bd. Pat. App. & Inter. 1990). Not only is the claimed compression not necessarily present, it is not even clear that any compression would be present given that Zdenek's disclosure, even with a convex surface, is directed to devices producing expansion, not compression. Rejections 3 and 4 similarly rely upon the teaching in Schachar "that a scleral prosthesis can have a convex bottom surface that would inherently Appeal 2014-006759 Reexamination Control 95/002,082 US Patent No. 7,736,389 B1 7 bend and compress the underlying portion of the sclera (see col. 5, lines 42- 50)." RAN 10. As with Zdenek, though Schachar does teach the possibility of a convex bottom surface, this surface exerts "an outward force on the scleral pocket to elevate the portion of the sclera attached thereto." Col. 5, ll. 42-50. Again, it is not even clear from Schachar that compression occurs, but whatever compression does occur is not the type claimed, seeing as Schachar is concerned with scleral expansion, not compression, to treat presbyopia. As the Patent Owner states, "[t]he examiner does not explain how the intrascleral device of Schachar '560 necessarily does both (1) treat presbyopia by expanding the sclera (through expansion from within the tunnel) and (2) inherently compresses the ciliary body so as to treat pre[s]byopia at the same time." App. Br. 23. Further to the alleged compression provided by Schachar, Zdenek, and Straub, we note that the Requester relies on the fact that Straub specifically contemplates compression due to its warning to avoid implantation where compression of the ciliary arteries or vasculature in the eye may occur. Resp. Br. 7. As Patent Owner rebuts, "[t]he references of Zdenek, Schachar, and Straub teach that compression does not treat presbyopia (but merely causes ischemia, as discussed by Straub)." Patent Owner's Rebuttal Br. 7. Accordingly, it is clear that any compression created by these references actually results, or may result, in the undesirable ischemia condition rather than effecting any type of compression that would result in treatment of presbyopia, thereby teaching away from such implementation. As such, we do not sustain rejections 1 and 3. Appeal 2014-006759 Reexamination Control 95/002,082 US Patent No. 7,736,389 B1 8 The Examiner also makes two rejections that add Caro (rejections 2 and 4) to the combinations of rejections 1 and 3. First, it is somewhat unclear why the Examiner adds Caro as the original combinations allegedly render the claims unpatentable without Caro. Further, as detailed below, the Examiner provides no rationale for adding Caro to the combinations. Although Caro teaches a convex bottom surface, as the Patent Owner states, "Figs. 4 and 5 of Caro clearly show that Caro's convex portion (42) should be about flush with the opposed feet (44) of the Caro device," whereas claim 1 requires that the convex center portion extend outwardly from the center portion. App. Br. 24. Patent Owner also points out correctly that Caro's ends are inserted into pockets in the eye, whereas the claimed device is sutured to the surface of the sclera using ends that urge the outwardly extending convex portion against the eye to effect the claimed compression. Id. Accordingly, whatever compression that is achieved by Caro is quite different from the expansion achieved by Zdenek or Schachar and also different from the claimed invention and we see no reason why one of skill in the art would attempt to combine the teachings of Zdenek or Schachar with the convex, but recessed, center portion of Caro. As stated supra, the Examiner provides no basis for the combinations that include Caro and only asserts, for example, that "the device of Schachar, when considered with the teachings of Straub and Caro regarding compression applied to the eye when the prosthesis is in use, is inherently capable of performing the recited compression function." RAN 14; see also RAN 9. We do not consider this to be a reasonable basis with rational underpinnings sufficient to support the combination of Zdenek or Schachar Appeal 2014-006759 Reexamination Control 95/002,082 US Patent No. 7,736,389 B1 9 and Straub with Caro. Additionally, Caro does not cure the deficiencies of the combinations noted above with respect to Zdenek or Schachar with Straub. Accordingly, we do not sustain rejections 3 and 4. DECISION For the above reasons, we REVERSE the Examiner’s decision to reject claim 1 as stated in each of rejections 1-4. No time period for taking any subsequent action in connection with this appeal may be extended under 37 C.F.R. § 1.136(a)(1)(iv). In the event neither party files a request for rehearing within the time provided in 37 C.F.R. § 41.79, and this decision becomes final and appealable under 37 C.F.R. § 41.81, a party seeking judicial review must timely serve notice on the Director of the United States Patent and Trademark Office. See 37 C.F.R. §§ 90.1 and 1.983. REVERSED PATENT OWNER: EDWIN H. CRABTREE 3773 CHERRY CREEK N. DRIVE SUITE 575 DENVER, CO 80209 REQUESTER: WILLIAM A. MUNCK, ESQ. C/O DOCKET CLERK P.O. DRAWER 800889 DALLAS, TX 75380 Copy with citationCopy as parenthetical citation